Triptolide avoids cisplatin resistance and induces apoptosis via the reactive oxygen species/nuclear factor-κB pathway in SKOV3PT platinum-resistant human ovarian cancer cells

Oncology Letters

Volumn 6, Issue 4, 2013, Pages 1084-1092

  Zhong, Yan Ying ^a   Chen, He Ping ^a   Tan, Bu Zhen ^a   Yu, Hai Hong ^a   Huang, Xiao Shan ^a  

^a NANCHANG UNIVERSITY   (China)

Author keywords

Nuclear factor B; Ovarian cancer; Platinum resistance; Reactive oxygen species; Triptolide

Indexed keywords

CISPLATIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROCASPASE 3; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; SYNAPTOTAGMIN I; TRIPTOLIDE; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LOW DRUG DOSE; MITOCHONDRION; OVARY CANCER; PROTEIN EXPRESSION; RESPIRATORY CHAIN; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 84881582988     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1524     Document Type: Article

References (51)

1. Cannistra SA: Cancer of the ovary. N Engl J Med 351: 2519-2529, 2004.
2. Shepherd JE: Current strategies for prevention, detection, and treatment of ovarian cancer. J Am Pharm Assoc (Wash) 40: 392-401, 2000.
3. Agarwal R and Kaye SB: Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer3: 502-516, 2003.
4. Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene22: 7265-7279, 2003.
5. Brabec V and Kasparkova J: Modifications of DNA by platinum complexes. Relation to resistance of tumors to platinum antitumor drugs. Drug Resist Updat 8: 131-146, 2005.
6. White KL, Rider DN, Kalli KR, Knutson KL, Jarvik GP and Goode EL: Genomics of the NF-κB signaling pathway: hypothesized role in ovarian cancer. Cancer Causes Control22: 785-801, 2011.
7. Nakanishi C and Toi M: Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 5: 297-309, 2005.
8. Li F and Sethi G: Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy. Biochim Biophys Acta 1805: 167-180, 2010.
9. Baud V and Karin M: Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 8: 33-40, 2009.
10. Yeh PY, Chuang SE, Yeh KH, Song YC, Ea CK and Cheng AL: Increase of the resistance of human cervical carcinoma cells to cisplatin by inhibition of the MEK to ERK signaling pathway partly via enhancement of anticancer drug-induced NF kappa B activation. Biochem Pharmacol63: 1423-1430, 2002.
11. Chen BJ: Triptolide, a novel immunosuppressive and anti-inflammatory agent purified from a Chinese herb Tripterygium wilfordii Hook F. Leuk Lymphoma 42: 253-265, 2001.
12. Chen YW, Lin GJ, Chia WT, Lin CK, Chuang YP and SytwuHK: Triptolide exerts anti-tumor effect on oral cancer and KB cells invitro and in vivo. Oral Oncol 45: 562-568, 2009.
13. Zhu W, Hu H, Qiu P and Yan G: Triptolide induces apoptosis in human anaplastic thyroid carcinoma cells by a p53-independent but NF-kappaB-related mechanism. Oncol Rep 22: 1397-1401, 2009.
14. Li H, Takai N, Yuge A, et al: Novel target genes responsive to the anti-growth activity of triptolide in endometrial and ovarian cancer cells. Cancer Lett 297: 198-206, 2010.
15. Kim MJ, Lee TH, Kim SH, Choi YJ, Heo J and Kim YH: Triptolide inactivates Akt and induces caspase-dependent death in cervical cancer cells via the mitochondrial pathway. Int J Oncol 37: 1177-1185, 2010.
16. Wu PP, Liu KC, Huang WW, et al: Triptolide induces apoptosis in human adrenal cancer NCI-H295 cells through a mitochondrial-dependent pathway. Oncol Rep 25: 551-557, 2011.
17. Antonoff MB, Chugh R, Borja-Cacho D, et al: Triptolide therapy for neuroblastoma decreases cell viability in vitro and inhibits tumor growth in vivo. Surgery 146: 282-290, 2009.
18. Lee KY, Park JS, Jee YK and Rosen GD: Triptolide sensitizes lung cancer cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by inhibition of NF-kappaB activation. Exp Mol Med 34: 462-468, 2002.
19. Morgan MJ and Liu ZG: Crosstalk of reactive oxygen species and NF-kappaB signaling. Cell Res 21: 103-115, 2011.
20. Kane DJ, Sarafian TA, Anton R, et al: Bcl-2 inhibition of neural death: decreased generation of reactive oxygen species. Science262: 1274-1277, 1993.
21. Liu GH, Wang SR, Wang B and Kong BH: Inhibition of nuclear factor-kappaB by an antioxidant enhances paclitaxel sensitivity in ovarian carcinoma cell line. Int J Gynecol Cancer16: 1777-1782, 2006.
22. Cohen GM: Caspases: the executioners of apoptosis. Biochem J 326: 1-16, 1997.
23. Riedl SJ and Shi Y: Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol 5: 897-907, 2004.
24. Fang J, Nakamura H and Iyer AK: Tumor-targeted induction of oxystress for cancer therapy. J Drug Target 15: 475-486, 2007.
25. Adam-Vizi V and Chinopoulos C: Bioenergetics and the formation of mitochondrial reactive oxygen species. Trends Pharmacol Sci 27: 639-645, 2006.
26. Silasi DA, Alvero AB, Rutherford TJ, Brown D and Mor G: Phenoxodiol: pharmacology and clinical experience in cancer monotherapy and in combination with chemotherapeutic drugs. Expert Opin Pharmacother 10: 1059-1067, 2009.
27. Sung B, Kunnumakkara AB, Sethi G, Anand P, Guha S and Aggarwal BB: Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model. Mol Cancer Ther8: 959-970, 2009.
28. Yang YI, Kim JH, Lee KT and Choi JH: Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species. Gynecol Oncol 123: 588-596, 2011.
29. Berkenblit A and Cannistra SA: Advances in the management of epithelial ovarian cancer. J Reprod Med 50: 426-438, 2005.
30. Yang M, Huang J, Pan HZ and Jin J: Triptolide overcomes dexamethasone resistance and enhanced PS-341-induced apoptosis via PI3k/Akt/NF-kappaB pathways in human multiple myeloma cells. Int J Mol Med 22: 489-496, 2008.
31. Chen YW, Lin GJ, Chuang YP, et al: Triptolide circumvents drug-resistant effect and enhances 5-fluorouracil antitumor effect on KB cells. Anticancer Drugs 21: 502-513, 2010.
32. Hampton MB and Orrenius S: Redox regulation of apoptotic cell death. Biofactors 8: 1-5, 1998.
33. Toyokuni S, Okamoto K, Yodoi J and Hiai H: Persistent oxidative stress in cancer. FEBS Lett 358: 1-3, 1995.
34. Fruehauf JP and Meyskens FL Jr: Reactive oxygen species: a breath of life or death? Clin Cancer Res 13: 789-794, 2007.
35. Maiti AK: Genetic determinants of oxidative stress-mediated sensitization of drug-resistant cancer cells. Int J Cancer130: 1-9, 2012.
36. Kurosu T, Fukuda T, Miki T and Miura O: BCL6 overexpression prevents increase in reactive oxygen species and inhibits apoptosis induced by chemotherapeutic reagents in B-cell lymphoma cells. Oncogene 22: 4459-4468, 2003.
37. Maiti AK: Gene network analysis of oxidative stress-mediated drug sensitivity in resistant ovarian carcinoma cells. Pharmacogenomics J 10: 94-104, 2010.
38. Xu B, Guo X, Mathew S, et al: Triptolide simultaneously induces reactive oxygen species, inhibits NF-kappaB activity and sensitizes 5-fluorouracil in colorectal cancer cell lines. Cancer Lett 291: 200-208, 2010.
39. Bao X, Cui J, Wu Y, et al: The roles of endogenous reactive oxygen species and nitric oxide in triptolide-induced apoptotic cell death in macrophages. J Mol Med (Berl) 85: 85-98, 2007.
40. Lau AT, Wang Y and Chiu JF: Reactive oxygen species: current knowledge and applications in cancer research and therapeutic. J Cell Biochem 104: 657-667, 2008.
41. Engel RH and Evens AM: Oxidative stress and apoptosis: a new treatment paradigm in cancer. Front Biosci 11: 300-312, 2006.
42. Dias N and Bailly C: Drugs targeting mitochondrial functions to control tumor cell growth. Biochem Pharmacol 70: 1-12, 2005.
43. Chen G, Zhang X, Zhao M, et al: Celastrol targets mitochondrial respiratory chain complex I to induce reactive oxygen species-dependent cytotoxicity in tumor cells. BMC Cancer 11: 170, 2011.
44. Mabuchi S, Ohmichi M, Nishio Y, et al: Inhibition of NFkappaB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models. J Biol Chem 279: 23477-23485, 2004.
45. Park B, Sung B, Yadav VR, Chaturvedi MM and AggarwalBB: Triptolide, histone acetyltransferase inhibitor, suppresses growth and chemosensitizes leukemic cells through inhibition of gene expression regulated by TNF-TNFR1-TRADD-TRAF2-NIK-TAK1-IKK pathway. Biochem Pharmacol82: 1134-1144, 2011.
46. Wang J, Zhou JY, Zhang L and Wu GS: Involvement of MKP-1 and Bcl-2 in acquired cisplatin resistance in ovarian cancer cells. Cell Cycle 8: 3191-3198, 2009.
47. Mansouri A, Zhang Q, Ridgway LD, Tian L and Claret FX: Cisplatin resistance in an ovarian carcinoma is associated with a defect in programmed cell death control through XIAP regulation. Oncol Res 13: 399-404, 2003.
48. Schreck R, Rieber P and Baeuerle PA: Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO J10: 2247-2258, 1991.
49. Van Waes C: Nuclear factor-kappaB in development, prevention, and therapy of cancer. Clin Cancer Res 13: 1076-1082, 2007.
50. Korn SH, Wouters EF, Vos N and Janssen-Heininger YM: Cytokine-induced activation of nuclear factor-kappa B is inhibited by hydrogen peroxide through oxidative inactivation of IkappaB kinase. J Biol Chem 276: 35693-35700, 2001.
51. Kapahi P, Takahashi T, Natoli G, et al: Inhibition of NF-kappa B activation by arsenite through reaction with a critical cysteine in the activation loop of Ikappa B kinase. J Biol Chem 275: 36062-36066, 2000.